Free Trial
→ Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th... (From Banyan Hill Publishing) (Ad)tc pixel Free FBT Stock Alerts

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (FBT) Competitors

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation logo
GBX 1,934 +0.60 (+0.03%)
As of 05/22/2026 11:26 AM Eastern
Compare

FBT vs. SOPH, PRSM, KAPE, KNOS, and TRST

Should you buy First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation stock or one of its competitors? MarketBeat compares First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation include Sophos Group plc (SOPH.L) (SOPH), Blue Prism Group (PRSM), Kape Technologies (KAPE), Kainos Group (KNOS), and Trustpilot Group (TRST). These companies are all part of the "software - application" industry.

How does First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation compare to Sophos Group plc (SOPH.L)?

Sophos Group plc (SOPH.L) (LON:SOPH) and First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) are both computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Sophos Group plc (SOPH.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sophos Group plc (SOPH.L)£726.90M0.00N/A£1.70N/A
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/AN/AN/A-£1.10N/A

In the previous week, Sophos Group plc (SOPH.L)'s average media sentiment score of 0.00 equaled First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation'saverage media sentiment score.

Company Overall Sentiment
Sophos Group plc (SOPH.L) Neutral
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Neutral

Company Net Margins Return on Equity Return on Assets
Sophos Group plc (SOPH.L)N/A N/A N/A
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation N/A N/A N/A

Summary

Sophos Group plc (SOPH.L) beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 3 of the 3 factors compared between the two stocks.

How does First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation compare to Blue Prism Group?

Blue Prism Group (LON:PRSM) and First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

In the previous week, Blue Prism Group's average media sentiment score of 0.00 equaled First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation'saverage media sentiment score.

Company Overall Sentiment
Blue Prism Group Neutral
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Neutral

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Blue Prism Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blue Prism Group£167.30M0.00N/A-£53.80N/A
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/AN/AN/A-£1.10N/A

Company Net Margins Return on Equity Return on Assets
Blue Prism GroupN/A N/A N/A
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation N/A N/A N/A

Summary

Blue Prism Group beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 2 of the 3 factors compared between the two stocks.

How does First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation compare to Kape Technologies?

Kape Technologies (LON:KAPE) and First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) are both small-cap computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

Kape Technologies has a net margin of 11.37% compared to First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's net margin of 0.00%. Kape Technologies' return on equity of 6.97% beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's return on equity.

Company Net Margins Return on Equity Return on Assets
Kape Technologies11.37% 6.97% 3.47%
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation N/A N/A N/A

Kape Technologies has higher revenue and earnings than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Kape Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kape Technologies£623.48M0.00£70.92M£0.15N/A
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/AN/AN/A-£1.10N/A

11.4% of Kape Technologies shares are held by institutional investors. 81.1% of Kape Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Kape Technologies' average media sentiment score of 0.00 equaled First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation'saverage media sentiment score.

Company Overall Sentiment
Kape Technologies Neutral
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Neutral

Summary

Kape Technologies beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 8 of the 8 factors compared between the two stocks.

How does First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation compare to Kainos Group?

Kainos Group (LON:KNOS) and First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) are both small-cap computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Kainos Group has higher revenue and earnings than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Kainos Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kainos Group£431.10M2.32£48.81M£24.8034.67
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/AN/AN/A-£1.10N/A

39.1% of Kainos Group shares are owned by institutional investors. 19.8% of Kainos Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Kainos Group has a net margin of 9.86% compared to First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's net margin of 0.00%. Kainos Group's return on equity of 41.45% beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's return on equity.

Company Net Margins Return on Equity Return on Assets
Kainos Group9.86% 41.45% 14.45%
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation N/A N/A N/A

Kainos Group presently has a consensus target price of GBX 1,173.40, indicating a potential upside of 36.48%. Given Kainos Group's stronger consensus rating and higher probable upside, analysts plainly believe Kainos Group is more favorable than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kainos Group
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Kainos Group's average media sentiment score of 0.50 beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's score of 0.00 indicating that Kainos Group is being referred to more favorably in the media.

Company Overall Sentiment
Kainos Group Positive
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Neutral

Summary

Kainos Group beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 12 of the 12 factors compared between the two stocks.

How does First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation compare to Trustpilot Group?

Trustpilot Group (LON:TRST) and First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) are both small-cap computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

Trustpilot Group has higher revenue and earnings than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Trustpilot Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trustpilot Group£261.05M3.48£20.08M£1.80130.00
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/AN/AN/A-£1.10N/A

Trustpilot Group presently has a consensus price target of GBX 321, suggesting a potential upside of 37.18%. Given Trustpilot Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe Trustpilot Group is more favorable than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trustpilot Group
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Trustpilot Group has a net margin of 2.97% compared to First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's net margin of 0.00%. Trustpilot Group's return on equity of 64.11% beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's return on equity.

Company Net Margins Return on Equity Return on Assets
Trustpilot Group2.97% 64.11% 1.45%
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation N/A N/A N/A

46.0% of Trustpilot Group shares are held by institutional investors. 18.6% of Trustpilot Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Trustpilot Group had 1 more articles in the media than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. MarketBeat recorded 1 mentions for Trustpilot Group and 0 mentions for First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. Trustpilot Group's average media sentiment score of 0.47 beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's score of 0.00 indicating that Trustpilot Group is being referred to more favorably in the media.

Company Overall Sentiment
Trustpilot Group Neutral
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Neutral

Summary

Trustpilot Group beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 13 of the 13 factors compared between the two stocks.

Get First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation News Delivered to You Automatically

Sign up to receive the latest news and ratings for FBT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FBT vs. The Competition

Export
MetricFirst Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationSoftware IndustryComputer SectorLON Exchange
Market Cap£793.36M£5.00B£39.65B£2.81B
Dividend YieldN/A3.97%3.19%6.08%
P/E Ratio-1,758.1826.7479.97365.78
Price / SalesN/A260.61624.0788,200.12
Price / Cash3.5417.2848.7227.89
Price / BookN/A4.3410.687.71
Net IncomeN/A£22.26M£1.06B£5.89B
7 Day Performance3.21%2.20%5.29%2.27%
1 Month Performance4.20%2.63%7.92%3.51%
1 Year Performance35.15%-8.07%173.40%79.62%

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FBT
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation
N/AGBX 1,934
+0.0%		N/A+35.2%£793.36MN/AN/A20
SOPH
Sophos Group plc (SOPH.L)
N/AN/AN/AN/A£2.99B£726.90M341.41520
PRSM
Blue Prism Group
N/AN/AN/AN/A£1.24B£167.30MN/A1,025
KAPE
Kape Technologies
N/AN/AN/AN/A£1.22B£623.48M1,900.00850
KNOS
Kainos Group
3.7497 of 5 stars		GBX 846
+3.2%		GBX 1,173.40
+38.7%		+20.5%£944.43M£431.10M34.112,953

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:FBT) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
More than 60 million Americans can position themselves before the 107x gold repricing.
Tucked inside U.S. Code Title 31, Section 5117 is a provision allowing the Treasury to reprice America's gold ...
Americas Gold Company | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
You cannot escape this reality
The last time something like this happened was 1974 - a secret deal that quietly determined the financial fate...
Porter & Company | Sponsoredtc pixel
Your $29.97 book is free today
Bill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...
Profits Run | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Nearly Half of Americans Are Exposed
Dr. David Eifrig, former Goldman Sachs insider and CEO of one of the largest financial research firms in the w...
Stansberry Research | Sponsoredtc pixel